Article Text

Download PDFPDF
Gamma knife radiosurgery for uveal melanoma: 12 years of experience
  1. G Modorati1,
  2. E Miserocchi1,
  3. L Galli2,
  4. P Picozzi3,
  5. P Rama1
  1. 1
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  2. 2
    Clinic of Infectious Diseases, Università Vita-Salute San Raffaele, Milan, Italy
  3. 3
    Department of Neurosurgery, San Raffaele Scientific Institute, Milan, Italy
  1. Dr G Modorati, Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy, Via Olgettina 60, 20132 Milan, Italy; modorati.giulio{at}


Aim: To present our treatment protocol and evaluate the results of Gamma knife radiosurgery (GKR) in treating patients with uveal melanoma.

Methods: Seventy-eight consecutive patients with uveal melanoma underwent stereotactic radiosurgery (radiation dose 30–50 Gy) with a Leksell Gamma-Knife at the San Raffaele University Hospital, Milan, Italy between 1994 and 2006. The main outcome measures evaluated were: survival rate, local tumour control, eye retention rate, visual acuity and treatment-related complications.

Results: Survival rate was 88.8% at 3 years and 81.9% at 5 years. Local tumour control was achieved in 91.0% of patients. The median tumour thickness reduction after treatment was 1.96 mm (p<0.0001) (−32.1%). The eye retention rate was 89.7%. A significant relative reduction of visual acuity was observed during follow-up. The most frequent treatment-related complications were: exudative retinopathy (33.3%), neovascular glaucoma (18.7%), radiogenic retinopathy (13.5%) and vitreous haemorrhages (10.4%).

Conclusion: GKR can be considered an alternative to enucleation for the treatment of choroidal melanomas.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Ethics approval: Ethics approval was provided by HSR Ethics Committee.

  • Patient consent: Obtained.